Cargando…
Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients—a prospective interventional study
Rivaroxaban, a direct oral anticoagulant, is effective against venous thromboembolism (VTE) recurrence without increasing the risk of major bleeding in patients with cancer-associated venous thromboembolism (CAT). However, its clot regression effects are poorly understood. This single-arm, prospecti...
Autores principales: | Takai, Shigeki, Nakanishi, Naohiko, Yokota, Isao, Imai, Kojiro, Yamada, Ayumu, Kawasaki, Takanori, Kasahara, Takeru, Okada, Takashi, Sawada, Takahisa, Matoba, Satoaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747974/ https://www.ncbi.nlm.nih.gov/pubmed/36513734 http://dx.doi.org/10.1038/s41598-022-26150-w |
Ejemplares similares
-
Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol
por: Takai, Shigeki, et al.
Publicado: (2019) -
Cavin-2 loss exacerbates hypoxia-induced pulmonary hypertension with excessive eNOS phosphorylation and protein nitration
por: Kasahara, Takeru, et al.
Publicado: (2023) -
A Simple Risk Stratification Model for ST-Elevation Myocardial Infarction (STEMI) from the Combination of Blood Examination Variables: Acute Myocardial Infarction-Kyoto Multi-Center Risk Study Group
por: Yanishi, Kenji, et al.
Publicado: (2016) -
The effectiveness of scoring balloon angioplasty in the treatment of chronic thromboembolic pulmonary hypertension
por: Takigami, Masao, et al.
Publicado: (2022) -
Pulmonary artery blood flow dynamics in chronic thromboembolic pulmonary hypertension
por: Tsubata, Hideo, et al.
Publicado: (2023)